Literature DB >> 12021627

Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication.

Theodor W May1, Bernhard Rambeck, Uwe Jürgens.   

Abstract

Topiramate is a new antiepileptic drug (AED) approved as add-on therapy. Previous studies have shown that topiramate has only a limited effect on other AEDs, but its own metabolism can be induced by enzyme-inducing drugs. The aim of this study was to investigate the influence of topiramate dose, age, and comedication, especially of carbamazepine, phenytoin, phenobarbital, oxcarbazepine, lamotrigine, and valproic acid (VPA) on topiramate serum concentrations in patients with epilepsy. In total, 480 samples of 344 inpatients who fulfilled the inclusion criteria (e.g., trough concentration, body weight available) were investigated. The topiramate serum concentration in relation to topiramate dose per body weight (level-to-dose ratio) was calculated and compared for patients receiving topiramate monotherapy and for patients receiving topiramate plus one other AED. Analysis of covariance (using age as covariate) showed that comedication had a highly significant influence on the topiramate serum concentrations. Regression analysis including all 480 samples confirmed that in combinations with phenytoin, carbamazepine, phenobarbital, and oxcarbazepine, the topiramate concentrations were significantly lower compared with topiramate monotherapy, whereas VPA and lamotrigine had no significant influence. Moreover, regression analysis indicated that primidone and methsuximide lowered topiramate concentrations, whereas gabapentin, bromide, and sulthiame did not. In addition to comedication, the patient's age was significantly correlated with topiramate clearance. In accordance with the results of previous studies, these results indicated that infants and children had lower topiramate concentrations than adults receiving the same topiramate dose per body weight. Comedication and age should be considered in adjusting topiramate dosage. Determination of topiramate serum concentrations may be useful, especially when enzyme-inducing drugs are withdrawn or added.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021627     DOI: 10.1097/00007691-200206000-00007

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  12 in total

1.  Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy.

Authors:  Yoshiaki Yamamoto; Yukitoshi Takahashi; Katsumi Imai; Masaaki Takahashi; Masahiko Nakai; Yushi Inoue; Yoshiyuki Kagawa
Journal:  Eur J Clin Pharmacol       Date:  2014-07-22       Impact factor: 2.953

2.  Molecular Correlates of Topiramate and GRIK1 rs2832407 Genotype in Pluripotent Stem Cell-Derived Neural Cultures.

Authors:  Richard Lieberman; Kevin P Jensen; Kaitlin Clinton; Eric S Levine; Henry R Kranzler; Jonathan Covault
Journal:  Alcohol Clin Exp Res       Date:  2020-08-09       Impact factor: 3.455

3.  Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data.

Authors:  Dina Battino; Danilo Croci; Alessandro Rossini; Sara Messina; Daniela Mamoli; Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.

Authors:  Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 5.  Pharmacokinetic interactions of topiramate.

Authors:  Meir Bialer; Dennis R Doose; Bindu Murthy; Christopher Curtin; Shean-Sheng Wang; Roy E Twyman; Stefan Schwabe
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update.

Authors:  Domenico Italiano; Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of oxcarbazepine.

Authors:  Theodor W May; Elisabeth Korn-Merker; Bernhard Rambeck
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 8.  [Drug interactions with antiepileptic agents].

Authors:  Klaus Turnheim
Journal:  Wien Klin Wochenschr       Date:  2004-02-28       Impact factor: 1.704

Review 9.  Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

10.  Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference.

Authors:  Steffen Naegel; Mark Obermann
Journal:  Neuropsychiatr Dis Treat       Date:  2010-02-03       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.